These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38674367)

  • 21. Molecular bases of pseudo-homozygous APC resistance: the compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma.
    Castoldi E; Kalafatis M; Lunghi B; Simioni P; Ioannou PA; Petio M; Girolami A; Mann KG; Bernardi F
    Thromb Haemost; 1998 Sep; 80(3):403-6. PubMed ID: 9759618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
    Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
    Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
    Delahousse B; Iochmann S; Pouplard C; Fimbel B; Charbonnier B; Gruel Y
    Blood Coagul Fibrinolysis; 1997 Nov; 8(8):503-9. PubMed ID: 9491268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Severe hereditary coagulation factor V deficiency caused by two novel heterozygous mutations].
    Zhou RF; Fu QH; Xu XC; Wang WB; Wu WM; Ding QL; Xie S; Zhai ZM; Hu YQ; Wang XF; Wu JS; Wang HL
    Zhonghua Xue Ye Xue Za Zhi; 2005 Mar; 26(3):129-32. PubMed ID: 15946520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and laboratory expression of associated thrombophilic conditions (homozygous/heterozygous factor V Leiden mutation and heterozygous prothrombin variant 20210A) in an Italian family.
    Simioni P; Tormene D; Luni S; Caldato M; Girolami A
    Blood Coagul Fibrinolysis; 2000 Jun; 11(4):379-84. PubMed ID: 10847426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of the p.Phe218Ser and p.Gly304Glu F5 Variants in Hereditary Factor V Deficiency.
    Dong R; Chen G; Jin Y; Wang M; Cheng X; Chen Y
    Acta Haematol; 2021; 144(6):712-716. PubMed ID: 34280927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three novel variants in the coagulation factor V gene associated with deep venous thrombosis in Chilean patients with Amerindian ethnic background.
    Guzmán N; Larama G; Ávila A; Salazar LA
    Clin Chim Acta; 2015 Apr; 444():24-8. PubMed ID: 25668227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.
    Castoldi E; Brugge JM; Nicolaes GA; Girelli D; Tans G; Rosing J
    Blood; 2004 Jun; 103(11):4173-9. PubMed ID: 14976057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombophilia as a multigenic disease.
    Zöller B; García de Frutos P; Hillarp A; Dahlbäck B
    Haematologica; 1999 Jan; 84(1):59-70. PubMed ID: 10091393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.
    Kabukcu S; Keskin N; Keskin A; Atalay E
    Clin Appl Thromb Hemost; 2007 Apr; 13(2):166-71. PubMed ID: 17456626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families.
    Koeleman BP; Reitsma PH; Allaart CF; Bertina RM
    Blood; 1994 Aug; 84(4):1031-5. PubMed ID: 8049422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor V and thrombotic disease: description of a janus-faced protein.
    Nicolaes GA; Dahlbäck B
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):530-8. PubMed ID: 11950687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
    Dahlbäck B
    Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model.
    van der Neut Kolfschoten M; Dirven RJ; Tans G; Rosing J; Vos HL; Bertina RM
    Blood Coagul Fibrinolysis; 2002 Apr; 13(3):207-15. PubMed ID: 11943934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival advantage of heterozygous factor V Leiden carriers in murine sepsis.
    Kerschen E; Hernandez I; Zogg M; Maas M; Weiler H
    J Thromb Haemost; 2015 Jun; 13(6):1073-80. PubMed ID: 25690763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis.
    Dahlbck B
    J Intern Med Suppl; 1997; 740():1-8. PubMed ID: 9350175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency.
    van Wijk R; Nieuwenhuis K; van den Berg M; Huizinga EG; van der Meijden BB; Kraaijenhagen RJ; van Solinge WW
    Blood; 2001 Jul; 98(2):358-67. PubMed ID: 11435304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besançon).
    Castoldi E; Hézard N; Mourey G; Wichapong K; Poggi M; Ibrahim-Kosta M; Thomassen MCLGD; Fournel A; Hayward CPM; Alessi MC; Hackeng TM; Rosing J; Morange PE
    J Thromb Haemost; 2021 May; 19(5):1186-1199. PubMed ID: 33605529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers.
    Mingozzi F; Legnani C; Lunghi B; Scanavini D; Castoldi E; Palareti G; Marchetti G; Bernardi F
    Thromb Haemost; 2003 Jun; 89(6):983-9. PubMed ID: 12783110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A.
    Lijfering WM; Middeldorp S; Veeger NJ; Hamulyák K; Prins MH; Büller HR; van der Meer J
    Circulation; 2010 Apr; 121(15):1706-12. PubMed ID: 20368522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.